Kirin (OTCMKTS:KNBWY) Shares Gap Up – Should You Buy?

Shares of Kirin Holdings Co. (OTCMKTS:KNBWY – Get Free Report) gapped up prior to trading on Monday. The stock had previously closed at $17.82, but opened at $18.41. Kirin shares last traded at $18.1450, with a volume of 2,309 shares.

Analyst Ratings Changes

Separately, Zacks Research downgraded Kirin from a “hold” rating to a “strong sell” rating in a research note on Monday, August 31st. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Kirin currently has a consensus rating of “Sell”.

Get Kirin alerts:

Get Our Latest Research Report on KNBWY

Kirin Price Performance

The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.02 and a current ratio of 1.48. The company has a 50-day moving average price of $18.63 and a 200-day moving average price of $17.35. The firm has a market capitalization of $14.63 billion, a P/E ratio of 11.50 and a beta of -0.01.

Kirin (OTCMKTS:KNBWY – Get Free Report) last announced its quarterly earnings results on Friday, August 7th. The company reported $0.58 earnings per share for the quarter, beating the consensus estimate of $0.42 by $0.16. The firm had revenue of $4.08 billion for the quarter, compared to analysts’ expectations of $3.87 billion. Kirin had a return on equity of 12.22% and a net margin of 7.79%. On average, sell-side analysts predict that Kirin Holdings Co. will post 1.34 earnings per share for the current year.

About Kirin

(Get Free Report)

Kirin Holdings Company, Limited is a Japan-based company with businesses spanning alcoholic and nonalcoholic beverages, pharmaceuticals and health science. Its beverage operations include beer, wine, spirits, soft drinks, bottled water and other consumer products marketed under brands such as Kirin, Ichiban Shibori and Afternoon Tea.

The company’s pharmaceutical business is conducted primarily through Kyowa Kirin, which researches, develops and commercializes prescription medicines, including treatments in areas such as oncology, immunology and nephrology.

Further Reading

• Five stocks we like better than Kirin
• Brewing Trouble? Starbucks Spills the Beans on 250 Store Closures
• Stitch Fix Stock Plunges as Guidance Puts the Turnaround on Pause
• Harley-Davidson Insiders Are Buying: Is HOG Finally Turning Around?
• 2 China-Focused ETFs For After the Trump-Xi Summit

Receive News & Ratings for Kirin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kirin and related companies with MarketBeat.com's FREE daily email newsletter.